ESMO 2017 : Adjuvant therapy with nivolumab superior to ipilimumab in surgically resected stage III and IV melanoma according to CheckMate 238 trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Adjuvant nivolumab is superior to ipilimumab in patients with surgically resected stage III or IV melanoma at high risk for relapse, according to the 18-months interim analysis from CheckMate 238 trial presented at ESMO 2017.

Why this matters

  • Ipilimumab is considered the st...